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MaPercutaneous coronary intervention (PCI) for chronic total occlusions (CTOs) has been rapidly evolving during recent
years. With improvement in equipment and techniques, high success rates can be achieved at experienced centers,
although overall success rates remain low. Prospective, randomized-controlled data regarding optimal use and
indications for CTO PCI remain limited. CTO PCI should be performed when the anticipated benefit exceeds the potential
risk. New high-quality studies of the clinical outcomes and techniques of CTO PCI are needed, as is the expansion of expert
centers and operators that can achieve excellent clinical outcomes in this challenging patient and lesion subgroup.
In the current review the authors summarize the latest publications in CTO PCI and provide an overview of the
current state of the field. (J Am Coll Cardiol Intv 2018;11:615–25) © 2018 the American College of Cardiology Foundation.
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ABBR EV I A T I ON S
AND ACRONYMS
CABG = coronary artery bypass
grafting
CTA = computed tomography
angiography
CTO = chronic total occlusion
IVUS = intravascular
ultrasound
MACE = major adverse cardiac
event(s)
MT = medical therapy
OMT = optimal medical therapy
PCI = percutaneous coronary
intervention
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616C hronic total occlusion (CTO) percu-taneous coronary intervention(PCI) is a rapidly evolving area of
interventional cardiology. We sought to pro-
vide an update on current concepts in CTO




CTOs are found in 16% to 52% of patients who
undergo coronary angiography and are found
to have coronary artery disease (1–3). In the
SCAAR (Swedish Coronary Angiography andAngioplasty Registry) registry, the prevalence of CTO
among patients with at least one 50% luminal coro-
nary stenosis was 16.1% (14,441 of 89,872 patients)
(4). In a Canadian single-center registry the preva-
lence of a CTO was 20%: PCI was performed in 9% of
these patients, 34% had coronary artery bypass
grafting (CABG), and 57% were treated with medical
therapy alone (5).
WHEN SHOULD CTO PCI BE PERFORMED?
CTO PCI should be performed when the anticipated
benefits (which depend on the patient’s baseline
clinical condition and the likelihood of success)
exceed the potential short- and long-term risks
(Central Illustration) (6).
CTO PCI BENEFITS: RANDOMIZED STUDIES.
Currently, symptom improvement is considered the
main benefit of CTO PCI, despite criticisms that there
is limited supportive prospective randomized-
controlled clinical trial data: indeed, only 3
randomized-controlled trials have been reported to
date, only 1 of which has been published (7).
The EXPLORE (Evaluating Xience and Left Ven-
tricular Function in Percutaneous Coronary Inter-
vention on Occlusions After ST-Elevation Myocardial
Infarction) trial enrolled 304 patients who underwent
primary PCI for acute ST-segment elevation acute
myocardial infarction and had a coexisting non–
infarct-related artery CTO. Patients were randomized
to CTO PCI versus medical therapy alone. CTO PCI
success was 73%. Cardiac magnetic resonance imag-
ing performed after 4 months showed similar left
ventricular ejection fraction and left ventricular end-
diastolic volume in the 2 study groups (7).
The DECISION-CTO (Drug-Eluting stent Implanta-
tion versus optimalMedical Treatment in patientswith
ChronIc Total OccluSION) trial (NCT01078051) waspresented at the 2017 American College of Cardiology
meeting. The DECISION-CTO trial randomized 834
patients with coronary CTOs (many of whom also had
multivessel disease) to optimal medical therapy (OMT)
alone versus OMT þ CTO PCI. Patients in the OMT and
theOMTþCTOPCI group had similar clinical outcomes
during a median follow-up of 3.1 years. The study has
several limitations, such as suboptimal primary
endpoint selection, high rate of non–CTO PCI (73% of
the study patients had multivessel disease in both
groups), early termination before achievement of
target enrollment, high crossover rates (18% in the
OMT alone group underwent CTO PCI), and mild
baseline symptoms in both study groups.
The EuroCTO (A Randomized Multicentre Trial to
Evaluate the Utilization of Revascularization or
Optimal Medical Therapy for the Treatment of Chronic
Total Coronary Occlusions) trial (NCT01760083) was
presented at the 2017 EuroPCR meeting. Due to slow
enrollment, the study ended prematurely after
randomizing 407 patients instead of the planned
1,200. In contrast to DECISION-CTO trial, non-CTO
lesions were treated before enrollment in the
study. Compared with patients randomized to
medical therapy only, patients randomized to CTO
PCI had more improvement in angina frequency at
12 months (p ¼ 0.009) as assessed by the Seattle
Angina Questionnaire.
CTO PCI BENEFITS: OBSERVATIONAL STUDIES.
Several observational, uncontrolled studies have
suggested clinical benefit with CTO PCI, by improving
angina, dyspnea, depression, exercise capacity, and
risk for arrhythmias.
Despite the limitation of comparing successful
with failed CTO PCIs, the OPEN-CTO (Outcomes, Pa-
tient Health Status, and Efficiency in Chronic Total
Occlusion Hybrid Procedures) registry analyzed 1,000
consecutive patients undergoing CTO PCI with the
hybrid approach (Figure 1) using standardized ques-
tionnaires. A 10.8-point (95% confidence interval: 6.3
to 15.3) improvement in the quality-of-life domain of
the Seattle Angina Questionnaire was observed
among successful versus unsuccessful procedures
(p < 0.001) (8). Similar results have been shown in
multiple prior studies and meta-analyses (9), which
have also reported lower mortality among successful
versus failed CTO PCIs (9). Several studies have
assessed the long-term outcomes of CTO PCI as
compared with medical therapy, reporting lower
incidence of major adverse cardiac events with CTO
PCI (10,11), even among patients with well-developed
collateral circulation (12). However, all retrospective
studies are subject to selection bias.
CENTRAL ILLUSTRATION Overview of the Potential Risks and Benefits of CTO PCI
Tajti, P. et al. J Am Coll Cardiol Intv. 2018;11(7):615–25.
Parameters that can help determine the risks and benefits of chronic total occlusion percutaneous coronary intervention. CABG ¼ coronary
artery bypass grafting; CTO ¼ chronic total occlusion; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention.
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617Patients with CTOs often have depression that
improves after successful CTO PCI (13). CTO PCI also
increases exercise capacity with longer 6-min walking
distance (417  126 m vs. 463  103 m; p ¼ 0.002) in
one study, likely due to lower angina frequency (39%
vs. 8%; p < 0.001) and less ischemia, especially in
patients with larger baseline ischemic burden (14).
Two studies performed cardiopulmonary testingbefore and after CTO PCI, showing increased peak
oxygen consumption and anaerobic threshold (15,16).
CTOs may be associated with higher arrhythmic risk:
patients with prior myocardial infarction and a CTO
had greater area of scar tissue (34 cm2 vs. 19 cm2;
p ¼ 0.001) and higher frequency of recurrent ven-
tricular tachycardia after ablation during a median










FIGURE 1 Hybrid Algorithm for CTO PCI
Dual angiography is performed and 4 parameters are assessed: proximal cap ambiguity, lesion length, quality of the distal vessel, and
presence of interventional collaterals. Based on these 4 parameters the initial crossing strategy is selected, followed by early change in case
of failure to achieve progress with any selected strategy. CART ¼ controlled antegrade and retrograde subintimal tracking. Reproduced with
permission from Brilakis (6).
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comes are significantly better after successful than
after failed CTO PCI (9), but such analyses have
multiple inherent limitations. Several other retro-
spective studies have compared the outcomes of CTO
PCI with medical therapy. In an Italian multicenter
registry of 1,777 patients with CTOs treatment was as
follows: PCI (43.7%), medical therapy (MT) (46.5%),
or surgery (9.8%). At 1-year follow-up, cardiac death
(1.4% vs. 4.7% and 6.3%; p < 0.001) and major
adverse cardiac events (MACE) (2.6% vs. 8.2% and
6.9%; p < 0.001) were significantly lower in the PCI
group than in MT or CABG groups (10). In propensity-
matched analysis MT was associated with higher
MACE rate, death, and rehospitalization (10). Similar
results were observed in patients with well-
developed collateral circulation (12).
In summary, CTO PCI improves patient symptoms,
whereas there is limited, retrospective data on
whether it can affect the subsequent incidence ofProcedural Outcomes From Multicenter CTO Registries Published in Rec





los et al. (19) 2012–2015 11 1,036 91% 90%
al. (23) 2012–2013 56 3,229 — 88%
al. (20) 2012–2014 7 1,156 90% —
s et al. (24) 2014–2015 17 1,253 89% 86%
al. (8) 2013–2017 12 1,000 86% 85%
nade rate was not reported. The rate of clinical perforation was 4.8%.
ronic total occlusion; MACE ¼ major adverse cardiovascular events; MI ¼ myocardial infracdeath, myocardial infarction, and arrhythmias.
Accordingly, the primary indication for offering and
performing CTO PCI should be the alleviation of
symptoms.
CTO PCI SUCCESS RATES. Achieving clinical benefit
with CTO PCI requires the procedure to be successful.
With contemporary equipment and techniques (e.g.,
the hybrid algorithm) (Figure 1) (18), high success
rates (85% to 90%) are achieved at experienced
centers (Table 1) (19–24). However, success rates in
unselected populations remain low: 61.3% in the New
York State PCI Registry (25) and 59% in the U.S. Na-
tional Cardiovascular Data Registry (vs. 96% in non-
occlusive lesions; p < 0.001) (26). Therefore, there is
a gap between what is achieved at dedicated CTO PCI
centers and the outcomes at less experienced cen-
ters. Bridging this gap remains a challenge and










1.7% 0.3% 0.7% 0.1% 0.2% 0.5%
0.5% 0.2% 0.1% 0.1% — 0.3%
1.6% 0.0% 0.8% 0.4% 0.0% 0.7%
2.6% 0.2% 0.2% 2.2% 0.1% 1.3%
7.0% 0.9% 2.6% 0.0% 0.1% —*
tion; TVR ¼ target vessel revascularization.









Stump morphology Blunt stump (1) Ambiguous
proximal cap (1)





Length >20 mm (1) — >20 mm (1) >20 mm (1.5) — >10 mm (1) $23 mm (2)
Ostial location Ostial location (1) Ostial location (1)















Calcification Mild to moderate (1) — Visible
calcification (1)






























Age, yrs — — — — $75 (1) — $65 (3)








































*Moderate-to-severe calcification is considered as part of the extended Ellis score. †Using specific collateral classification scoring (range 0–2) combining Werner collateral classification (82), collateral type
(septal, epicardial, other), and tortuosity. Each number in parentheses reflects the points added if the lesion has this parameter.
CABG ¼ coronary artery bypass grafting; CL score ¼ clinical and lesion related score; CTO ¼ chronic total occlusion; J-CTO ¼Multicenter CTO Registry of Japan; LAD ¼ left anterior descending artery; MI ¼
myocardial infarction; ORA ¼ ostial location, collateral filling of Rentrop <2, age over 75; PCI ¼ percutaneous coronary intervention; PROGRESS ¼ PROspective Global REgiStry for the Study of Chronic Total
Occlusion Intervention; RECHARGE ¼ REgistry of Crossboss and Hybrid Procedures in FrAnce, the NetheRlands, BelGium and UnitEd Kingdom.
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619Patient-specific estimation of the likelihood of
success can be facilitated by using various scoring
systems (Table 2). The first CTO PCI score was the
J-CTO (Multicenter CTO Registry of Japan) score that
was developed to estimate the likelihood of successful
guidewire crossing within 30 min based on 5
criteria (intralesion >45 bend, length >20 mm,
calcification, blunt stump, and previously failed
attempt) (27). The J-CTO score has been validated in
other CTO PCI cohorts (28) and is also associated with
1-year clinical outcomes (29), although prior failure
was not associated with lower success rates in another
study (30). Other scores include the PROGRESS-CTO
(PROspective Global REgiStry for the Study of
Chronic Total Occlusion Intervention) score (31), the
RECHARGE (REgistry of Crossboss and Hybrid Pro-
cedures in FrAnce, the NetheRlands, BelGium and
UnitEd Kingdom) registry score (32), the CL score
(Clinical and Lesion related score) (33), and the ORA
(ostial location, collateral filling of Rentrop <2, age
over 75 years) score (34). Ellis at al. (35) used a novel
approach for developing a scoring system forpredicting CTO PCI technical success by stratifying
lesions according to proximal cap ambiguity. Param-
eters associated with technical success were poor
distal target, lesion length$10 mm, and ostial location
in CTOs with proximal cap ambiguity versus worse
collateral score and excess retrograde tortuosity in
CTOs without proximal cap ambiguity (35). One study
showed that various scores had similar predictive ca-
pacity for technical success and that they performed
better in antegrade-only cases (36).
CTO PCI success scores should ideally be used for
estimating success in patients and operators similar
to the ones used for their development. They may be
of most value for less experienced operators for
selecting which cases to perform and which to refer or
perform with a proctor. Moreover, they can assist
with procedural planning (e.g., scheduling multiple
highly complex CTO PCIs on the same day should be
avoided).
COMPLICATIONS. CTO PCI is associated with
higher risk for complications as compared with PCI
FIGURE 2 Perforation Management Algorithm
The first step in management of coronary perforations is balloon inflation to stop bleeding into the pericardium, followed by fluid/vasopressor
administration, pericardiocentesis in case of hypotension and notification of cardiac surgery in case emergency surgery is needed. If the
perforation is not sealed further management depends on perforation type: large vessel perforations are usually treated with a covered stent
whereas distal vessel perforations are treated with embolization. Anticoagulation should not be reversed until all equipment is removed from
the coronary arteries to minimize the risk for coronary thrombosis. Reproduced with permission from Brilakis (6).
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620of non-CTO lesions (26). The average risk is
approximately 3%, but varies widely between
studies (Table 1). Patient-specific risk estimates can
be calculated by using a dedicated scoring system,
such as the PROGRESS-CTO complications score
that uses 3 variables (age $65 years, lesion length
>23 mm, and application of retrograde approach)
(37). Ellis et al. (35) reported the following 2 inde-
pendent correlates of complications: moderate to
severe lesion calcium, and low left ventricular
ejection fraction.
Perforat ion . Coronary perforation is the most feared
complication of CTO PCI (38) and our understanding of
its diagnosis and treatment has significantly evolved in
recent years. Coronary perforations during CTO PCI
can be classified as large vessel, distal vessel, and
collateral vessel perforations (6). The first step in any
coronary perforation is inflation of a balloon to prevent
additional bleeding into the pericardium (Figure 2).
Subsequent treatment of large vessel perforations is
usually achieved with covered stents and for distal
vessel perforations with fat or coil embolization.
Delivery of a covered stent was traditionally achieved
using a dual guide catheter technique (balloon infla-
tion through one guide catheter to tamponade the
perforation and advancement of a covered stentthrough a second guide catheter). With development
of lower profile covered stents (rapid exchange Graft-
Master, Abbott Vascular, Santa Clara, California), both
a balloon and a covered stent can now be delivered
through a single 8-F guide catheter (“block-and-
deliver” technique) (39). Similarly, for distal vessel
perforation balloon occlusion and coil or fat delivery
can be achieved through a single guide catheter (40).
Collateral vessel perforation can be challenging to treat
(22,41): epicardial collateral perforations require
treatment from both directions to achieve sealing
usually with coils, fat, or thrombin (42).
Coronary perforations in prior CABG patients have
traditionally been considered less perilous, due to the
belief that pericardial adhesions would prevent
development of tamponade. Newer reports suggest
that perforation in prior CABG patients may actually
carry increased risk for major complications, because
pericardial adhesions may result in formation of
loculated hematomas that can cause localized tam-
ponade and cardiogenic shock. Such hematomas are
not amenable to drainage by pericardiocentesis and
computed tomography–guided drainage or surgery
may be required to drain the effusion (43–45).
Intramural bleeding should be considered if there is
no pericardial effusion by echocardiography, but
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621the clinical picture is suggestive of pericardial tam-
ponade (46).
Side branch occlus ion and myocard ia l infarct ion.
CTO lesions involve bifurcations frequently (in
approximately a third of cases) (47). Side branch oc-
clusion can affect both the acute and the long-term
outcomes of CTO PCI and is more frequent with
dissection reentry (both antegrade and retrograde)
techniques and stenting over the side branch (48).
PCI of CTOs that involve a bifurcation has also been
associated with higher risk for perforation and tam-
ponade (49).
Myocardial infarction during CTO PCI is more
common with use of the retrograde approach (50,51)
and has been associated with worse subsequent
clinical outcomes in most (52–54) studies.
Radiat ion sk in in jury . CTO PCIs are often long
procedures with high patient (and operator) radiation
dose (55). High radiation dose may lead to acute
dermatitis of the exposed area that can progress to
chronic skin ulcer and even require surgical inter-
vention. In a study of 2,124 patients undergoing 2,579
PCIs (including 238 CTO PCIs), a chronic skin ulcer
developed in 0.34% (9 patients, 5 of which were CTO
PCIs with skin lesion onset after 1 to 3 months of in-
terventions) requiring surgical intervention in 8 of
them (56). Most operators currently recommend
stopping the procedure after reaching 7- or 8-Gy air
kerma dose. It is also recommended to monitor the
patient for radiation skin injury if >4- or 5-Gy air
kerma dose is administered. With use of newer x-ray
equipment, low cine and fluoroscopy frame rate, and
meticulous attention to technique, radiation dose can
be significantly reduced (57). Additionally, the use of
disposable sterile radiation shields during CTO PCI
can reduce operator radiation dose to levels similar to
those of non-CTO PCIs (58).
RISK-BENEFIT RATIO. The decision about whether to
perform CTO PCI should be individualized, starting
with a thorough clinical and angiographic assessment
to determine the potential clinical benefit (symptom
improvement in most cases), likelihood of success,
and risk for complications. CTO PCI should be offered
to patients who have more to gain than to lose
(Central Illustration).
CTO PCI TECHNIQUES
ACCESS SITE. Access site selection is important in
CTO PCI for providing appropriate support, and
allowing enough space for simultaneous use of multi-
ple devices. Many operators recommend 8-F guiding
catheters, mostly via transfemoral access, even thoughthey may carry higher risk for vascular complications
(59). Fluoroscopic guidance before puncture using
surgical forceps was associated with ideal access
position in >93% of 528 patients undergoing CTO
PCI, and low (0.89%) incidence of adverse events (60).
In one study transradial CTO PCI was effective in
appropriately selected cases (61), however the more
complex lesions were performed using bifemoral
access. In another study that compared transradial
(n ¼ 280) and transfemoral (n ¼ 305) CTO PCIs,
although technical success was similar in the 2 access
groups (74.6% vs. 72.5%; p ¼ 0.51), complex (J-CTO
score $3) cases performed using transradial access
had significantly lower technical success rates than
those done using transfemoral access (35.7% vs. 58.2%;
p ¼ 0.004) (62). Many operators are currently per-
forming biradial CTO PCI using 7-F slender sheaths
(Terumo, Somerset, New Jersey) or sheathless 8-F
transradial guide catheters. Transradial access can
and is increasingly being used for CTO PCI among
expert transradial operators (63), but may be associ-
ated with lower success and efficiency (63), especially
in complex cases.
CTO CROSSING TECHNIQUES. There are 3 major
techniques for crossing CTOs: antegrade wire escala-
tion, antegrade dissection or re-entry, and the retro-
grade approach (6). Algorithms, such as the hybrid
algorithm (18) and the Asia Pacific CTO algorithm
(http://apcto.club/apcto-algorithm/), have been
developed for choosing the initial crossing technique
based on the angiographic characteristics of the
occlusion.
The retrograde approach carries higher risk for
periprocedural complications as compared with
antegrade only approaches. In an analysis from the
PROGRESS-CTO registry the risk was 4-fold higher
with retrograde versus antegrade cases driven by
higher risk for myocardial infarction and perforation
requiring pericardiocentesis (64). The risk is higher
with use of epicardial as compared with septal
collateral (22), hence septal collateral vessels and
bypass grafts (65) are preferred for retrograde
crossing, when available. The retrograde approach
remains critical for achieving high success rates,
especially in more complex CTOs (19,20), and is
associated with favorable long-term outcomes (21).
The relative merits of antegrade wire escalation
versus antegrade dissection/re-entry remain contro-
versial. The hybrid algorithm currently recommends
use of antegrade dissection or re-entry for $20 mm
long lesions with clear proximal cap and good
quality distal vessel; and antegrade wire escalation
for <20 mm long lesions. The CrossBoss First trial
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comparing the 2 approaches and demonstrated similar
crossing time, similar success and complication rates
and similar equipment utilization and cost in the 2
study groups. However, crossing was faster with the
CrossBoss catheter in patients with CTOs due to in-
stent restenosis. Similar to retrograde crossing, ante-
grade dissection or re-entry is more frequently used in
more complex lesions (20,28). Extensive dissection or
re-entry strategies, such as subintimal tracking and re-
entry carry increased risk for periprocedural myocar-
dial infarction due to side branch loss (67) and high
restenosis and reocclusion rates and are currently only
used as bailout (68).
IMAGING. Intravascular imaging is used in CTO PCI
to guide crossing and for stent optimization. Intra-
vascular ultrasound (IVUS) can help determine the
location of the proximal cap, direct the guidewire
within the occlusion and confirm distal true lumen
position after crossing (67,69). Use of IVUS for CTO
crossing can be challenging and requires expertise in
image interpretation as well as use of large guide
catheters that can accommodate the IVUS probe
together with microcatheters and guidewires.
The role of IVUS for stent optimization during CTO
PCI was recently evaluated in 2 randomized trials.
Kim et al. (70) randomized 402 patients undergoing
CTO PCI to IVUS guidance (n ¼ 201) or angiographic
guidance alone (n ¼ 201) and reported lower inci-
dence of MACE in the IVUS-guided group (2.6% vs.
7.1%; p ¼ 0.0035; hazard ratio: 0.35; 95% confidence
interval: 0.13 to 0.97). The AIR-CTO (Study comparing
Angiography- vs. IVUS- and/or FFR-guided stent im-
plantation for chronic total occlusion in coronary ar-
tery) study randomized 230 patients to IVUS-guided
(n ¼ 115) versus angiography-guided (n ¼ 115) stent
implantation after successful CTO crossing. During a
follow-up of 12 months IVUS use was associated with
lower in-stent late lumen loss (0.28  0.48 mm vs.
0.46  0.68 mm; p ¼ 0.025), in-stent restenosis (3.9%
vs. 13.7%; p ¼ 0.021), and stent thrombosis (0.9% vs.
6.1%; p ¼ 0.043) (71). Similar to non-CTO lesions,
achieving good stent expansion is associated with
lower rates for restenosis (72).
The role of coronary computed tomography angi-
ography (CTA) in CTO PCI continues to evolve. Scores
have been developed to predict CTO PCI success
based on coronary CTA characteristics and measure-
ments (73); however, further evaluation are needed in
larger patient cohorts. Fusion of coronary CTA-
derived images with coronary angiography during
PCI could potentially facilitate CTO crossing at-
tempts. Kim et al. (74) used coronary CTA imaging tolocalize the guidewire within the lesion in 61 patients,
and their method proved to be helpful in identifying
not just single antegrade wires, but parallel or retro-
grade wires as well. Cases performed with coronary
CTA coregistration tended to have higher technical
success (83% vs. 63%; p ¼ 0.147).
In summary, imaging can play a significant role in
CTO PCI for procedural planning (coronary CTA),
guiding CTO crossing (coronary CTA and IVUS), and
optimizing the final stent result (IVUS), that can
translate into better long-term outcomes.
OPTIMAL STENTING IN CTO PCI. Restenosis after
CTO PCI with bare-metal stents was approximately
50%, but with use of drug-eluting stents, clinical
outcomes have significantly improved with low rates
of restenosis, reocclusion, and target vessel revascu-
larization (75). The vessel distal to the occlusion often
enlarges after restoration of antegrade flow (76),
suggesting that residual distal stenoses post–CTO PCI
that do not affect antegrade flow may not require
stenting. Few cases of “crushing” a previously
implanted stent after substent crossing have been
reported with promising mid-term results, but further
assessment is required to understand the long-term
outcome of this technique (77–79).
TRAINING AND EDUCATION. Given the complexity
of CTO PCI, becoming and remaining successful CTO
operator requires appropriate training and continued
practice, both for achieving high success rates (23)
and also for minimizing the risk for complications
and efficiently managing them if they occur (25,26).
Optimal training for CTO PCI remains controversial,
as there are few dedicated fellowship programs.
Most operators learn CTO PCI after being in practice
for a few years through participation in courses and
proctoring. In a study of 587 CTO PCIs, operators
who were proctored in the hybrid approach had
higher procedural success (77.5% vs. 62.1%;
p < 0.0001), especially in more complex cases
(J-CTO score $2: 70.7% vs. 49.5%; p ¼ 0.0003), with
similar periprocedural complication rates. Further-
more, they were more willing to perform CTO PCI,
even in complex occlusions (J-CTO score $3: 15%
before vs. 30% after proctorship; p < 0.0001) (80).
Live case demonstrations are an integral part of
CTO PCI courses raising concerns for adverse patient
outcomes. Shimura et al. (81) compared the outcomes
of live case demonstrations of CTO PCI (n ¼ 199) with
cases that were not performed live (n ¼ 540). Proce-
dural success (91.5% vs. 86.7%; p ¼ 0.076), 30-day
mortality (0% vs. 0.7%; p ¼ 0.28), and complications
rates, such as dissection (p ¼ 0.53), perforation
(p ¼ 0.12), or cardiac tamponade (p ¼ 0.40), were
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623similar in the 2 groups, suggesting that live case
demonstrations are safe.
In summary, upfront training and continuous ed-
ucation through publications, online resources (e.g.,
www.ctomanual.org, www.ctofundamentals.org and
http://apcto.club/apcto-algorithm/), live case dem-
onstrations, CTO PCI workshops, and proctorships are
essential for acquiring, maintaining, and improving
the operators’ skills, leading to higher success and
lower complication rates.
CONCLUSIONS
CTO PCI is a rapidly evolving field. With improvement
in equipment and techniques, high success rates can
be achieved at experienced centers, although success
rates remain low in unselected centers, a gap thatneeds to be bridged through innovation and educa-
tion. Prospective, randomized-controlled data
regarding optimal use and indications of CTO PCI
remain limited. Further high-quality studies of CTO
PCI are needed, as well as expansion of expert centers
and operators that can achieve excellent clinical
outcomes in this challenging patient-and-lesion sub-
group. In the meantime, thoughtful and detailed
consideration of the potential risks and benefits of the
procedure (Central Illustration) can optimize clinical
decision making for each individual patient with
coronary CTOs.
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